Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction
Background. XXI century is known as a century of obesity and type 2 diabetes (T2D), one of the main reasons of nonalcoholic fatty liver disease (NAFLD). Severe forms of NAFLD, such as non-alcoholic steatohepatitis and cirrhosis, are associated with process of apoptosis. A great contributor in the de...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Scientific Сentre for Family Health and Human Reproduction Problems
2018-02-01
|
| Series: | Acta Biomedica Scientifica |
| Subjects: | |
| Online Access: | https://www.actabiomedica.ru/jour/article/view/547 |
| _version_ | 1797237346279620608 |
|---|---|
| author | M. A. Cherepanova |
| author_facet | M. A. Cherepanova |
| author_sort | M. A. Cherepanova |
| collection | DOAJ |
| description | Background. XXI century is known as a century of obesity and type 2 diabetes (T2D), one of the main reasons of nonalcoholic fatty liver disease (NAFLD). Severe forms of NAFLD, such as non-alcoholic steatohepatitis and cirrhosis, are associated with process of apoptosis. A great contributor in the developing of NAFLD is a dysfunction of hematolymphatic barrier and linagliptin showed positive effect on this. The group of inhibitors of apoptosis - Bcl-2 resists to wide variety of pro-apoptotic proteins. Studying correction of apoptosis can be the key to the treatment of NAFLD, and that is a reason of high interest in anti-apoptotic Bcl-2 protein. Aims. To assess the features of the expression of the anti-apoptotic Bcl-2 protein in the liver of db/db mice in the model of obesity and type 2 diabetes mellitus and with linaglyptin correction. Materials and methods. Experiment was performed on type 11 (db/db) diabetic mice. Linaglyptin or placebo was administered daily by gavage from the 8th to 16th weeks of life. Results. The week immunohistochemical reaction for antiapoptotic protein Bcl-2 was found in placebo-treated mice. Whereas treatment with Linaglyptin shifted the ratio of apoptosis regulators following significant increase in the area of Bcl-2 expression. Conclusions. The obtained results demonstrate a "try" at antiapoptotic activity of the Linaglyptin in the liver in the model of T2D. |
| first_indexed | 2024-03-08T12:18:07Z |
| format | Article |
| id | doaj.art-885df33e57d1482cb29c0868ac9d9967 |
| institution | Directory Open Access Journal |
| issn | 2541-9420 2587-9596 |
| language | Russian |
| last_indexed | 2024-04-24T17:18:17Z |
| publishDate | 2018-02-01 |
| publisher | Scientific Сentre for Family Health and Human Reproduction Problems |
| record_format | Article |
| series | Acta Biomedica Scientifica |
| spelling | doaj.art-885df33e57d1482cb29c0868ac9d99672024-03-28T07:49:19ZrusScientific Сentre for Family Health and Human Reproduction ProblemsActa Biomedica Scientifica2541-94202587-95962018-02-013111611910.29413/ABS.2018-3.1.18547Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correctionM. A. Cherepanova0Scientific Institute of Clinical and Experimental LymphologyBackground. XXI century is known as a century of obesity and type 2 diabetes (T2D), one of the main reasons of nonalcoholic fatty liver disease (NAFLD). Severe forms of NAFLD, such as non-alcoholic steatohepatitis and cirrhosis, are associated with process of apoptosis. A great contributor in the developing of NAFLD is a dysfunction of hematolymphatic barrier and linagliptin showed positive effect on this. The group of inhibitors of apoptosis - Bcl-2 resists to wide variety of pro-apoptotic proteins. Studying correction of apoptosis can be the key to the treatment of NAFLD, and that is a reason of high interest in anti-apoptotic Bcl-2 protein. Aims. To assess the features of the expression of the anti-apoptotic Bcl-2 protein in the liver of db/db mice in the model of obesity and type 2 diabetes mellitus and with linaglyptin correction. Materials and methods. Experiment was performed on type 11 (db/db) diabetic mice. Linaglyptin or placebo was administered daily by gavage from the 8th to 16th weeks of life. Results. The week immunohistochemical reaction for antiapoptotic protein Bcl-2 was found in placebo-treated mice. Whereas treatment with Linaglyptin shifted the ratio of apoptosis regulators following significant increase in the area of Bcl-2 expression. Conclusions. The obtained results demonstrate a "try" at antiapoptotic activity of the Linaglyptin in the liver in the model of T2D.https://www.actabiomedica.ru/jour/article/view/547type 2 diabetesliverlinagliptinapoptosis |
| spellingShingle | M. A. Cherepanova Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction Acta Biomedica Scientifica type 2 diabetes liver linagliptin apoptosis |
| title | Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction |
| title_full | Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction |
| title_fullStr | Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction |
| title_full_unstemmed | Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction |
| title_short | Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction |
| title_sort | peculiarities of the antiapoptotic bcl 2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction |
| topic | type 2 diabetes liver linagliptin apoptosis |
| url | https://www.actabiomedica.ru/jour/article/view/547 |
| work_keys_str_mv | AT macherepanova peculiaritiesoftheantiapoptoticbcl2proteinexpressioninliverinamodelofobesityandtype2diabetesandwithlinaglyptincorrection |